— Why it moved
Why LPCN Stock Spiked and Faded Today — October 7, 2026
Lipocine got Canadian regulatory approval for its testosterone drug, popped early in the morning, and spent the rest of the day flushing every penny away.
What moved LPCN stock
Lipocine is a clinical-stage biopharma outfit focused on metabolic and endocrine disorders. Health Canada approved their oral testosterone capsule, TLANDO, which commercial partner Verity Pharma plans to launch by the end of the year. That early press release got traders excited for about five minutes.
The mechanics
A tight float of 6.5 million shares combined with a tiny 30-day average volume created a 53.33 percent morning gap. Churning through 105 million shares shattered liquidity and left bagholders trapped everywhere.
LPCN by the numbers
The alert window
The alert went out at 7:27 AM at $3.72. The stock dipped to $3.62 before squeezing to a peak of $3.99 at 7:32 AM, offering a razor-thin 7.3 percent move over five minutes. Bids vanished immediately, leaving just seven total minutes above the alert price.
How LPCN's move ended
By the closing bell, LPCN collapsed to $2.19, finishing down 41.1 percent from the alert price. A Canadian drug approval through a licensing partner does not fix heavy cash burn or long-term dilution risk.
The tell: Premarket biopharma approvals on micro-caps almost always peak before regular trading even starts.